BMS-193884 - CAS 176960-47-7
Catalog number: 176960-47-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H17N3O4S
Molecular Weight:
395.43
COA:
Inquire
Targets:
Endothelin Receptor
Description:
BMS-193884, an oxazol derivative, has been found to be an endothelin A receptor antagonist and was once studied in the treatmen of heart failure.
Purity:
98%
Appearance:
Powder
Synonyms:
BMS-193884; BMS 193884; BMS193884; 7ON53PV45J; SCHEMBL4204130; BDBM50091105; N-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[4-(1,3-oxazol-2-yl)phenyl]benzenesulfonamide
Storage:
Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).
MSDS:
Inquire
Quality Standard:
In-house standard
Quantity:
Milligram-Grams
InChIKey:
LJGUZUROJOJEMI-UHFFFAOYSA-N
InChI:
InChI=1S/C20H17N3O4S/c1-13-14(2)22-27-19(13)23-28(24,25)18-6-4-3-5-17(18)15-7-9-16(10-8-15)20-21-11-12-26-20/h3-12,23H,1-2H3
Canonical SMILES:
CC1=C(ON=C1C)NS(=O)(=O)C2=CC=CC=C2C3=CC=C(C=C3)C4=NC=CO4
1.Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists.
Murugesan N;Gu Z;Stein PD;Spergel S;Mathur A;Leith L;Liu EC;Zhang R;Bird E;Waldron T;Marino A;Morrison RA;Webb ML;Moreland S;Barrish JC J Med Chem. 2000 Aug 10;43(16):3111-7.
The synthesis and structure-activity relationship (SAR) studies of a series of 4'-oxazolyl-N-(3,4-dimethyl-5-isoxazolyl)[1, 1'-biphenyl]-2-sulfonamide derivatives as endothelin-A (ET(A)) receptor antagonists are described. The data reveal a remarkable improvement in potency and metabolic stability when the 4'-position of the biphenylsulfonamide is substituted with an oxazole ring. Additional 2'-substitution of an acylaminomethyl group further increased the binding activity and provided one of the first subnanomolar ET(A)-selective antagonists in the biphenylsulfonamide series (17, ET(A) K(i) = 0.2 nM). Among the compounds described, 3 (N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)[1, 1'-biphenyl]-2-sulfonamide; BMS-193884) had the optimum pharmacological profile and was therefore selected as a clinical candidate for studies in congestive heart failure.
2.Application of structure-metabolism relationships in the identification of a selective endothelin A antagonist, BMS-193884, with favourable pharmacokinetic properties.
Humphreys WG;Obermeier MT;Barrish JC;Chong S;Marino AM;Murugesan N;Wang-Iverson D;Morrison RA Xenobiotica. 2003 Nov;33(11):1109-23.
1. Based on binding affinity, 2'-amino-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1,1'-biphenyl]-2-sulfonamide (2) was identified as an initial lead in a programme to identify selective endothelin (ET) receptor antagonists. However, the compound was extensively metabolized in preclinical animal species and human in vitro systems due to oxidative biotransformation. 2. To optimize this structural class, the site of metabolism of 2 was determined. This allowed for focussed structure-activity and structure-metabolism studies aimed at finding more metabolically stable analogues that maintained potency. New analogues were screened for their ET binding characteristics and their stability in rat and human liver microsomes. 3. The use of the microsomal stability screen was tested by the determination of the pharmacokinetic parameters of select analogues. A good correlation was found between reduced rates of rat microsomal metabolism and reduced clearance in the rat. 4. N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide (3) was identified as an analogue with improved in vitro properties and further studies revealed that the compound had improved pharmacokinetic properties.
3.Endothelin-1 and right-sided heart failure in rats: effects of an endothelin receptor antagonist on the failing right ventricle.
Miyauchi T;Sato R;Sakai S;Kobayashi T;Ueno M;Kondo H;Kawano S;Goto K;Yamaguchi I J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S327-30.
The development of pulmonary hypertension (PH) causes right-sided heart failure. We investigated whether chronic treatment with the endothelin-A- (ETA) receptor antagonist BMS-193884 in rats with monocrotaline- (MCT) induced PH improves right-sided heart failure. Administration of BMS-193884 (100mg/kg) was commenced on the day before treatment with MCT. At 19 days, hemodynamics were measured under anesthesia and hearts were removed. The right ventricular systolic pressure (RVSP), an indicator for pulmonary hypertension, was remarkably elevated in the PH group compared with the normal control group. BMS-193884 effectively prevented this elevation. The central venous pressure, an indicator for right-sided heart failure, was markedly increased in the PH group. This increase was reduced to the normal level by BMS-193884. In the failing right ventricle of the PH group, the expression of atrial natriuretic peptide (ANP) mRNA, which is a molecular marker for the failing heart, was markedly increased. BMS-193884 greatly prevented this increase. The present study suggests that ET-1 contributes to the right-sided heart failure caused by PH and that an ETA-receptor antagonist is a beneficial drug which improves both hemodynamics and cardiac gene expression in the failing right ventricle.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Endothelin Receptor Products


CAS 1103522-45-7 N-Despropyl-macitentan

N-Despropyl-macitentan
(CAS: 1103522-45-7)

N-Despropyl-macitentan, an active metabolite of Macitentan, is a dual ET receptor antagonist with longer half-life than Macitentan. It has been proved to be eff...

CAS 169545-27-1 IRL-2500

IRL-2500
(CAS: 169545-27-1)

IRL-2500, an indol derivative, has been found to be an endothelin B receptor antagonist that was once studied in hypertension.

CAS 157659-79-5 SB-209670

SB-209670
(CAS: 157659-79-5)

SB-209670 has been found to be an endothelin receptor antagonist that was once studied against arrhythmias and hypertension.

CAS 143113-45-5 BQ-3020

BQ-3020
(CAS: 143113-45-5)

BQ-3020 is a potent and selective ETB endothelin receptor agonist (Ki = 0.18 and 970 nM at human ETB and ETA receptors, respectively).

T-0201 Sodium
(CAS: 188307-16-6)

The sodium salt form of T-0201 which has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied...

CAS 126738-34-9 Sarafotoxin S6a

Sarafotoxin S6a
(CAS: 126738-34-9)

Sarafotoxin S6a is an endothelin receptor agonist (EC50 = 7.5 and > 150 nM for contraction of pig coronary artery and guinea pig aorta, respectively).

CAS 195733-43-8 Atrasentan hydrochloride

Atrasentan hydrochloride
(CAS: 195733-43-8)

Atrasentan hydrochloride is the hydrochloride salt form of Atrasentan. Atrasentan, also called as ABT-627, is a selective and orally available antagonist of ETA...

CAS 254740-64-2 Sparsentan

Sparsentan
(CAS: 254740-64-2)

Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.

Chemical Structure

CAS 176960-47-7 BMS-193884

Quick Inquiry

Verification code

Featured Items